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Summary
There is a close cross-talk between complement, Toll-like receptors (TLRs) 
and coagulation. The role of the central complement component 5 (C5) 
in physiological and pathophysiological hemostasis has not, however, been 
fully elucidated. This study examined the effects of C5 in normal hemo-
stasis and in Escherichia coli-induced coagulation and tissue factor (TF) 
up-regulation. Fresh whole blood obtained from six healthy donors and 
one C5-deficient individual (C5D) was anti-coagulated with the thrombin 
inhibitor lepirudin. Blood was incubated with or without E. coli in the 
presence of the C5 inhibitor eculizumab, a blocking anti-CD14 monoclonal 
antibody (anti-CD14) or the TLR-4 inhibitor eritoran. C5D blood was 
reconstituted with purified human C5. TF mRNA was measured by quan-
titative polymerase chain reaction (qPCR) and monocyte TF and CD11b 
surface expression by flow cytometry. Prothrombin fragment 1+2 (PTF1·2) 
in plasma and microparticles exposing TF (TF-MP) was measured by 
enzyme-linked immunosorbent assay (ELISA). Coagulation kinetics were 
analyzed by rotational thromboelastometry and platelet function by PFA-
200. Normal blood with eculizumab as well as C5D blood with or without 
reconstitution with C5 displayed completely normal biochemical hemostatic 
patterns. In contrast, E. coli-induced TF mRNA and TF-MP were signifi-
cantly reduced by C5 inhibition. C5 inhibition combined with anti-CD14 
or eritoran completely inhibited the E. coli-induced monocyte TF, TF-MP 
and plasma PTF1·2. Addition of C5a alone did not induce TF expression 
on monocytes. In conclusion, C5 showed no impact on physiological he-
mostasis, but substantially contributed to E. coli-induced procoagulant 
events, which were abolished by the combined inhibition of C5 and CD14 
or TLR-4.
Keywords: CD14, complement C5, Escherichia coli, tissue factor, Toll-like 
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Introduction
Sepsis is still a major threat to human health, and the 
incidence is rising [1]. It is commonly associated with 
coagulation disturbances ranging from coagulation activa-
tion to disseminated intravascular coagulation [2]. Tissue 
factor (TF) is suggested to be a major initiator of bacteria-
induced coagulation in human sepsis [3].
TF initiates the extrinsic coagulation pathway and results 
in thrombin activation and clot formation. We have pre-
viously demonstrated that the Escherichia coli-induced 
coagulation in human whole blood measured by pro-
thrombin fragment 1+2 (PTF1·2) is TF-dependent, using 
a blocking antibody against TF [4]. The E. coli-induced 
monocyte TF surface expression was efficiently inhibited 
by the combined inhibition of complement C3 and CD14 
[4]. Furthermore, the Neisseria meningitidis-induced mono-
cyte TF surface expression was largely complement com-
ponent 5 (C5)-dependent [5].
The complement system is a complex plasma cascade 
and an important component of innate immunity. The 
system is activated via three routes, the classical, 
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alternative and lectin pathways, all leading to the acti-
vation of C5 and the terminal pathway [6]. The terminal 
complement C5b-9 complex (TCC) can either be depos-
ited on a surface as the membrane attack complex (MAC) 
or remain in the fluid phase as soluble TCC (sC5b-9) 
[6]. Complement opsonizes bacteria, enhances phago-
cytosis and may induce MAC-mediated lysis of some 
complement-sensitive bacteria, in particular Neisseria 
species [7]. Activation of C5 also induces formation of 
C5a, which is an important proinflammatory mediator 
with a wide range of effects on host cells, particularly 
leukocytes [8].
There are many links between the complement and 
coagulation systems [9], but the role of C5 in normal 
coagulation kinetics and hemostasis is only partially inves-
tigated. One reason for this is that genetic deficiency of 
C5 is extremely rare [10]. However, clinical use of the 
anti-C5 antibody eculizumab (Soliris®) is considerably 
increasing the patient population with a ‘functional’ C5 
deficiency and, thus, increasing the relevance of studies 
on complement in hemostasis. Muhlfelder et al. showed 
that C5 increased the TF activity on leukocytes [11], due 
most probably to activation of C5a receptor type 1 (C5aR1) 
[5,12].
Earlier studies have suggested that C6-deficient rabbits 
had an increased tendency to bleed, as prolonged clotting 
time and reduced prothrombin consumption were 
observed, and reconstitution with purified C6 corrected 
this condition [13]. Furthermore, C6-deficient mice and 
rats also had prolonged bleeding [14]. In contrast, humans 
with complement C6-deficiency [15,16] and a C7-deficient 
individual [17] were shown to have normal hemostasis. 
Zymosan failed to aggregate platelets in both C3, C5, C6 
and C7-deficient plasmas, suggesting a role of C5 in platelet 
aggregation [18].
Combined inhibition of C3 and CD14 significantly 
inhibited the E. coli-induced cytokine release, phagocytosis 
and oxidative burst in human whole blood [19]. CD14 
is the co-receptor of several Toll-like receptors (TLRs), 
including TLR-4 and TLR-2 [20], indicating that TLRs 
may be involved in the E. coli-induced TF 
up-regulation.
The aim of this study was to investigate how C5 affects 
normal hemostasis and coagulation kinetics, and the roles 
of C5 as well as CD14 and TLR-4 in bacteria-induced 
coagulation in fresh human whole blood from healthy 
controls or a C5-deficient individual (C5D).
Materials and methods
Blood sampling for hemostasis investigations
Venous blood from the male C5D individual, who was 
diagnosed due to repeated meningococcal sepsis [10], and 
healthy controls (one male and five females) for hemostasis 
investigation were collected in tubes with 3·2% sodium 
citrate (Vacuette; Greiner Bio-One GmbH, 
Kremensmünster, Austria). The tubes were centrifuged at 
2500  g for 10  min at room temperature. The study was 
approved by the regional ethics committee of the Northern 
Norway Regional Health Authority. The donors provided 
written informed consent.
Whole blood experiments and inhibitors
Whole blood experiments were performed according to 
the previously described whole blood model [21]. Blood 
was collected in 4·5 ml Nunc polypropylene tubes (Roskilde, 
Denmark) containing a 50  mg/l final concentration of 
lepirudin (Refludan®; Celgene, Uxbridge, UK). All equip-
ment and reagents were endotoxin-free. Blood (975  µl) 
was preincubated for 5  min with 195  µl of phosphate-
buffered saline (PBS; Sigma-Aldrich, St Louis, MO, USA) 
or inhibitor. Anti-human C5 IgG2/4 eculizumab (Alexion 
Pharma GmbH, New Haven, CT, USA) was used at a 
final concentration of 77  mg/l, an immunoglobulin (Ig)
G2/4 isotype control antibody (NHDL, produced in our 
laboratory) at 77  mg/l, anti-human CD14 IgG2/4 r18D11 
(anti-CD14 [22]) at 15  mg/l and the TLR-4 inhibitor 
eritoran (E5564, kindly provided from Eisai, Andover, 
MA, USA) at 1   µM. PMX53 [AcF-(OPdChaWR)] was 
synthesized as described previously [23], purified by 
reverse-phase high-performance liquid chromatography, 
and used at a final concentration of 10  µM. In experi-
ments with blood from the C5D, purified human C5 at 
a final concentration of 50 mg/l (Complement Technology, 
Tyler, TX, USA) or 17·5  mg/l human serum albumin 
(HSA) (Octapharma, Lachen, Switzerland) were added. 
After preincubation, 195  µl of PBS, heat-inactivated E. 
coli (final concentration 1  ×  107/ml; strain LE392, ATCC 
33572; American Type Culture Collection, Manassas, VA, 
USA) [21] or ultrapure lipopolysaccharide (LPS) (final 
concentration 100  ng/ml; LPS-EB Ultrapure from E. coli 
strain 0111; InvivoGen, Eugene, OR, USA) were added. 
The time zero sample (T0) was processed immediately 
after blood sampling. Samples for flow cytometric analysis 
of CD11b surface expression were incubated at 37°C for 
10  min. All other samples were incubated at 37°C and 
tilted up and down 10 times per min on a Rock-n-Roller 
(Labinco, Breda, the Netherlands) for 120  min before 
further processing. For flow cytometric analysis of TF, 
45  µl of whole blood was added to 5  µl citrate. For 
analysis of PTF1·2, soluble TCC, cytokines and TF mRNA, 
ethylenediamine-tetraacetic acid (EDTA, 10 mM final 
concentration) was added to stop further coagulation and 
complement activation. All tubes were centrifuged at 
3000  g at 4°C for 20  min, and plasma was stored at 
–80°C until analysis, except for quantitative PCR (qPCR) 
analysis. Here, the volume of plasma removed above the 
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blood cells was replaced with PBS without CaCl2 and 
MgCl2 and TempusTM blood RNA solution (Applied 
Biosystems, Foster City, CA, USA) was added at twice 
the blood volume. The tubes were stored at –20°C until 
analysis. For analysis of TF function in plasma micro-
particles (TF-MP), 25  µl citrate solution was added to 
225  µl blood. The tubes were centrifuged twice, first at 
1500  g at room temperature for 15  min to remove cells. 
The plasma was centrifuged a second time at 13  000  g 
at room temperature for 2  min and the supernatant was 
stored at –80°C until analysis.
Coagulation analyses
Routine coagulation analyses were performed in citrated 
plasma using a STA-R Evolution® instrument and reagents 
from Diagnostica Stago (Asniéres, France). STA® SPA+ 
reagent was used for prothrombin time-international nor-
malized ratio (PT-INR), and STA®-PPT for activated partial 
thromboplastin time (APTT; Diagnostica Stago) and clot 
detection methods. The colorimetric kits STACHROM® 
protein C and STACHROM® ATIII (Diagnostica Stago) 
were used for analysis of protein C and anti-thrombin 
III, respectively. The clot-based test kit STACLOT® protein 
S (Diagnostica Stago) and the COATEST® APCTM 
Resistance V kit from Chromogenix (Bedford, MA, USA) 
were used for analysis of protein S and activated protein 
C (APC) resistance, respectively. FVIII, von Willebrand 
factor antigen and activity, lupus anti-coagulant, anti-
cardiolipin IgG and IgM and anti-beta2-glycoprotein I 
IgG and IgM were estimated in blood samples from the 
C5D individual by routine analyses at the Department 
of Medical Biochemistry, Oslo University Hospital, Oslo, 
Norway.
Thromboelastometry on whole blood
Clot development in fresh citrated blood was analyzed 
using ROTEM® delta (Tem Innovations GmbH, Munich, 
Germany) following the manufacturer’s instructions. The 
non-activated thromboelastometry (NATEM) analyses 
were performed as previously described [24,25]. Star-tem 
reagent (Tem Innovations GmbH) containing CaCl2 was 
used to recalcify the samples.
Platelet function analysis in whole blood
Platelet function in whole blood was analyzed using the 
INNOVANCE® PFA200 instrument from Siemens 
Healthcare (Marburg, Germany) and Dade PFA collagen/
ADP test cartridges (Siemens Healthcare). The test mimics 
venous damage and platelet adhesion and aggregation 
repair of a vessel injury. Closure time is the time before 
the hole in the cuvette is closed by platelets, and the 
results are given in seconds.
Real-time quantitative polymerase chain reaction 
(qPCR) of TF mRNA levels
The MagMaxTM for stabilized Blood Tubes RNA Isolation 
kit from Thermo Fisher Scientific (Vilnius, Lithuania) was 
used to isolate the RNA. The concentration of RNA was 
measured using a Nanodrop 2000c (Thermo Fisher 
Scientific, Wilmington, DE, USA). The TaqMan® RNA–
CTTM 1-step kit (Applied Biosystems) was used to analyze 
the TF and control mRNA levels from 2  ng of total RNA 
per sample. Hs00175225_m1 (Applied Biosystems) was used 
to amplify the TF mRNA. Human beta-2-microglobulin 
(Hu B2 M; Applied Biosystems) was used as an endog-
enous control, as it is stably expressed in the whole blood 
model [26]. The samples were analyzed in triplicate using 
QuantStudio 6 Flex from Applied Biosystems. The delta-
delta Ct-method was used to calculate the relative con-
centration of TF mRNA. The results are given as relative 
quantitation (RQ), using the PBS control sample incubated 
for 120  min at 37°C as a calibrator and set to 1.
Flow cytometric analysis of TF surface expression
The monocyte TF surface expression in whole blood 
(12·5 µl) was analyzed by adding fluorescein isothiocyanate 
(FITC)-labeled anti-human TF antibody (2·5 µl) (product 
no. 4508CJ, clone VD8; American Diagnostica, Inc., 
Stamford, CT, USA) or a FITC-labeled mouse IgG1 isotype 
control antibody (2·5  µl) (Becton Dickinson, San Jose, 
CA, USA). To gate the monocytes and leukocytes, phy-
coerythrin (PE) (Becton Dickinson)-labeled anti-CD14 
antibody (2·5 µl) and peridinin-chlorophyll (PerCP)-labeled 
anti-CD45 antibody (2·5  µl) (Becton Dickinson) were 
added to the blood samples in a 96-well microtiter plate 
(Nunc) and incubated in the dark for 15  min at room 
temperature. The samples were lysed by adding EasyLyse™ 
(250  µl) (S2364; Dako Cytomation, Glostrup, Denmark) 
and incubated for 15  min at room temperature protected 
from light. The samples were centrifuged at 300  g for 
5 min and washed with PBS containing 0·1% (w/v) bovine 
serum albumin (BSA), and the cells were resuspended in 
PBS. The samples were analyzed using a BD LSR II flow 
cytometer (Becton Dickinson) and results expressed as 
median fluorescence intensity (MFI). The MFI results are 
given as the differences between the MFI with anti-TF 
antibody and the isotype control antibody.
Flow cytometric analysis of CD11b surface expression
Increasing amounts of human recombinant C5a (Hycult 
Biotechnology, Uden, the Netherlands) were added to 
blood from healthy donors. After a 10-min incubation 
at 37°C, 25  µl whole blood was added to 25  µl 0·5% 
(v/v) paraformaldehyde (PFA; Sigma Aldrich, Oslo, 
Norway), and cells were fixed at 37°C for 4  min. The 
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fixed blood cells were stained with PE-labeled anti-CD11b 
(Becton Dickinson) or PE-labeled mouse IgG2a (Becton 
Dickinson) in the dark for 15  min at room temperature. 
In addition, PerCP-labeled CD45 (Becton Dickinson) and 
FITC-labeled anti-CD14 (Becton Dickinson; clone MP9) 
were used to gate leukocytes and monocytes. The samples 
were mixed with 1  ml PBS and analyzed using NovoCyte 
flow cytometer (ACEA Biosciences, Inc., San Diego, CA, 
USA) and results recorded as the median fluorescence 
intensity (MFI).
Enzyme-linked immunosorbent assays (ELISA)
Soluble TCC levels were measured in plasma using an 
antibody against a specific C9 neoepitope in the TCC 
complex, as described previously [27]. PTF1·2 in plasma 
was measured using an Enzygnost®F1+2 (monoclonal) kit 
from Siemens Healthcare (Marburg, Germany). The PTF1·2 
results in Fig. 2b,d were normalized to the sample incu-
bated for 120  min at 37°C with E. coli, which was set 
to 100%. TF-MP was measured in plasma using the 
Zymuphen MP-TF kit (Aniara Diagnostica, West Chester, 
OH, USA). Optical density was measured using an MRX 
microplate reader (Dynex Technologies, Denkendorf, 
Germany).
Statistical analysis
Analysis of normality distribution was performed using 
the Shapiro–Wilk test in IBM spss Statistics for Windows 
version 22·0 (IBM Corp., Armonk, NY, USA). If the 
normality test failed, the results were log-transformed. 
The results that were still skewed were analyzed using 
non-parametric tests. Data were analyzed using 
GraphPad Prism version 6·0 (GraphPad Software, San 
Diego, CA, USA). The results from experiments with 
stimuli were analyzed with a paired Student’s t-test 
comparing the results with and without E. coli or LPS 
and the exact P-value is reported. Wilcoxon’s matched-
pairs signed-rank test was used to analyze non-para-
metric data. Furthermore, a one-way repeated-measures 
analysis of variance (anova) and Dunnett’s multiple 
comparisons test using PBS as a control were used to 
compare the effects of various additives. Non-parametric 
data were analyzed using Friedman’s test and Dunn’s 
multiple comparisons test. The Pearson correlation in 
GraphPad Prism was used to analyze the correlation 
between coagulation measured as PTF1·2 and the mono-
cyte TF surface expression or TF-MP in plasma. Two-
way repeated-measures anova and Sidak’s multiple 
comparison tests were used to compare results in the 
presence or absence of the C5a receptor 1 (C5aR1) 
antagonist PMX53 at different C5a concentrations. A 
P-value below 0·05 was considered statistically 
significant.
Results
No impact of C5 on hemostasis or coagulation kinetics 
under physiological conditions
Samples from the healthy blood donors were within the 
reference ranges for the selected routine coagulation analy-
sis (Table 1). Plasma from the C5D individual displayed 
normal coagulation measured by PT-INR, APTT, protein 
C, protein S and anti-thrombin levels, APC resistance, 
von Willebrand factor activity, lupus anti-coagulant and 
D-dimer (Table 1).
Analyses of coagulation kinetics in fresh blood from 
both the healthy donors and the C5D using thrombo-
elastometry and platelet function analyzer showed that C5 
had no apparent impact on clot formation and platelet 
aggregation under physiological conditions (Table 2). A 
statistical comparison of the ROTEM results in the C5D 
and the six healthy donors after adding eculizumab was 
not possible due to data from only one C5D individual.
C5 inhibition and absence of C5 (C5D) reduced the  
E. coli-induced TF whole blood mRNA levels and 
monocyte TF surface expression
Incubation for 120  min with E. coli significantly 
(P  =  0·0056) increased the TF mRNA level in blood 
from healthy donors compared with control samples 
incubated with PBS (Fig. 1a). Eculizumab significantly 
(P  <  0·05) reduced the E. coli-induced TF mRNA level 
from 6·4 to 1·9 RQ compared to PBS, whereas the con-
trol antibody had no effect. In blood from healthy donors, 
monocyte TF surface expression was significantly 
(P  =  0·0002) increased from MFI  =  88 in the PBS con-
trol to MFI  =  851 in the presence of E. coli (Fig. 1b). 
Eculizumab significantly (P  <  0·05) reduced the E. coli-
induced TF surface expression to MFI  =  327, whereas 
the control antibody had no effect. Eculizumab completely 
blocked the E. coli-induced complement activation meas-
ured as formation of sC5b-9 in plasma (data not shown).
In blood from the C5D individual, E. coli increased 
the TF mRNA level from 1·0 to 7·5 RQ (Fig. 1c). After 
reconstitution with purified C5, the E. coli-induced TF 
mRNA level further increased to 23·4 RQ. Monocyte TF 
surface expression increased in the presence of E. coli to 
MFI  =  232 compared to MFI  =  59 in the PBS control 
(Fig. 1d). Reconstitution with purified C5 further increased 
the E. coli-induced TF surface expression to MFI  =  470. 
The HSA control had no effect on either E. coli-induced 
TF mRNA or monocyte TF surface expression.
C5 inhibition and absence of C5 (C5D) reduced the  
E. coli-induced TF-MP and PTF1·2 levels
Incubation of whole blood from healthy donors with 
E. coli for 120  min significantly (P  =  0·0002) increased 
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the levels of TF-MP from 0·84 to 8·8 pg/ml (Fig. 2a). 
Eculizumab significantly (P  <  0·05) reduced the E. coli-
induced TF-MP levels to 4·9 pg/ml, whereas the control 
antibody had no effect. The impact of C5 inhibition on 
coagulation was evaluated by analyzing the PTF1·2 levels 
in plasma (Fig. 2b). E. coli significantly (P < 0·05) increased 
the PTF1·2 levels from 4·4% in the PBS control to 100% 
after 120  min incubation with E. coli (set to 100%). 
Eculizumab significantly (P  <  0·05) reduced the E. coli-
induced PTF1·2 level to 44% of the PBS control. The 
control antibody had no effect on the E. coli-induced 
PTF1·2 level; however, the results displayed high biological 
variation.
In blood from the C5D, E. coli increased the TF-MP 
levels from 0·36 to 2·9  pg/ml (Fig. 2c). After reconstitu-
tion with purified C5, E. coli increased the TF-MP levels 
from 2·9 to 5·7  pg/ml and the PTF1·2 level from 100% 
in the absence of recombinant C5 to 471% in C5 recon-
stituted blood (Fig. 2d). In the absence of E. coli and 
C5, PTF1·2 were 12% of the sample incubated with E. 
coli. The HSA control had no effect on either the E. 
coli-induced TF-MP or E. coli-induced PTF1·2 levels.
E. coli-induced PTF1·2 levels correlated with 
procoagulant activity of TF-MP
We then tested if the functional measure of coagulation 
activation, reflected by plasma PTF1·2, correlated signifi-
cantly with TF surface expression on monocytes and 
TF-MP. Data for PTF1·2, TF-MP and monocyte TF surface 
expression from one experiment with each blood donor 
were included in the correlation analysis (n  =  6). PTF1·2 
did not correlate with TF surface expression on monocytes 
(r  =  0·49, P  >  0·05, Fig. 3a), but with TF-MP levels 
(r  =  0·85, P  =  0·0319, Fig. 3b).
Recombinant human C5a increased the CD11b surface 
expression but not monocyte TF surface expression in 
whole blood
We next examined if recombinant human C5a alone 
enhanced the TF surface expression on monocytes. The 
effect of increasing doses of C5a on TF and CD11b sur-
face expression on monocytes in human whole blood was 
examined using flow cytometry. CD11b surface expression 
was used as a control readout, as C5a was reported to 
enhance CD11b surface expression [28]. Human C5a 
increased CD11b surface expression from MFI  =  3187 at 
baseline to MFI  =  9161 after a 10-min incubation with 
the highest C5a concentration in a dose-dependent man-
ner (Fig. 4). The C5aR1 antagonist PMX53 significantly 
(P  <  0·05) reduced C5a-induced CD11b expression on 
monocytes. In contrast, TF surface expression was 
unchanged after a 120-min incubation with C5a and 
PMX53 had no effect (Fig. 4).
The combination of TLR-4- and C5-inhibition reduced 
E. coli-induced monocyte TF surface expression, 
TF-MP and plasma PTF1·2
We then examined the possible additional role for C5 
and TLR-4 and its co-receptor CD14 on the E. coli-induced 
monocyte TF surface expression using the TLR-4/MD2-
specific inhibitor eritoran and a blocking anti-CD14 mAb 
(Fig. 5). As a positive control, the effect of TLR-4 inhibi-
tion on ultrapure E. coli LPS-induced monocyte TF surface 
expression, TF-MP levels and PTF1·2 was also 
examined.
Eculizumab alone and anti-CD14 alone did not sig-
nificantly reduce the E. coli-induced monocyte TF surface 
expression, whereas the combination significantly 
(P  <  0·05) reduced the monocyte TF surface expression 
from MFI  =  1066 to MFI  =  176 (Fig. 5a). Eritoran 
alone did not significantly reduce the E. coli-induced 
monocyte TF surface expression, whereas combined with 
eculizumab the reduction was significant (P  <  0·05) to 
MFI  =  227.
Eculizumab alone significantly (P  <  0·05) reduced the 
E. coli-induced TF-MP from 9·0 to 6·4  pg/ml (Fig. 5b). 
Anti-CD14 alone did not significantly reduce TF-MP, 
whereas combined with eculizumab the reduction from 
9·0 to 3·4 pg/ml was significant (P < 0·05). Eritoran alone 
did not significantly reduce TF-MP, whereas combined 
with eculizumab the reduction from 9·0 to 3·8  pg/ml was 
significant (P  <  0·05). The control antibody unexpectedly 
and significantly increased (P  <  0·05) the E. coli-induced 
TF-MP.
Eculizumab alone and anti-CD14 alone did not sig-
nificantly reduce the E. coli-induced PTF1·2, whereas 
the combination significantly (P  <  0·05) reduced the 
PTF1·2 from 18·8 to 2·7  nmol/ml analyzed by anova 
(Fig. 5c). However, a paired Student’s t-test showed 
that eculizumab alone significantly (P = 0·0356) reduced 
the E. coli-induced PTF1·2 (Fig. 5c). Eritoran alone did 
not significantly reduce the PTF1·2, whereas combined 
with eculizumab the reduction from 18·8 to 4·0  nmol/
ml was significant (P  <  0·05).
Eritoran significantly (P  <  0·05) reduced LPS-induced 
monocyte TF surface expression (Fig. 5a), LPS-induced 
TF-MP (Fig. 5b) and LPS-induced PTF1·2 (Fig. 5c). Data 
on LPS and E. coli-induced monocyte TF surface expres-
sion were displayed in representative histograms for one 
donor (Fig. 6).
Discussion
The present data demonstrate that blood from a 
C5-deficient (C5D) individual displayed completely normal 
concentrations of hemostatic proteins and functional 
hemostatic analyses as normal individuals. Consistently, 
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C5 had no impact on the physiological coagulation kinet-
ics in vitro using whole blood samples from healthy con-
trols inhibited with eculizumab. In contrast, C5 was 
crucially important in the E. coli-induced hemostatic 
disturbance, reflected by increased TF mRNA generation, 
monocyte TF surface expression, plasma TF-MP and 
PTF1·2 formation. The effect of C5 was most pronounced 
at the mRNA level. Finally, combined inhibition of C5 
Fig. 1. Effect of the anti-human C5 antibody eculizumab and C5 deficiency on Escherichia coli (E. coli)-induced tissue factor (TF) mRNA levels and 
monocyte TF surface expression on whole blood monocytes. Whole blood from healthy donors was preincubated with phosphate-buffered saline 
(PBS), eculizumab (Eculiz.) or control antibody (Ctrl.Ab.). The blood samples were either processed immediately (time zero samples) or incubated 
for 120 min at 37°C with PBS (control) or 1 × 107/ml E. coli. TF mRNA expression (a,c) was examined using real-time quantitative PCR (qPCR) and 
expressed as the relative quantity (RQ) compared to the PBS control (set to 1). Monocyte TF surface expression (b,d) was examined using flow 
cytometry and given as median flow intensity (MFI). Whole blood from the C5-deficient individual was incubated with PBS, purified complement 
component C5 or human serum albumin (HSA) prior to incubation with E. coli (c,d). The results are given as means ± standard deviation (s.d.) for 
normal blood experiments (n = 6), and as mean (line) and scatterplot of two experiments performed on two different days with C5D blood. 
*P < 0·05.
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and CD14 or TLR-4 most efficiently blocked the E. coli-
induced coagulation, with only minor effects of each 
inhibitor alone.
Inhibition of complement with eculizumab emerges 
as an important strategy for treatment of an increasing 
number of diseases involving complement activation, 
and is Food and Drug Administration (FDA)-approved 
for clinical use with paroxysmal nocturnal hemoglobi-
nuria (PNH), atypical hemolytic uremic syndrome and 
myasthenia gravis [29,30]. Here, we show that the 
Fig. 2. Effect of the anti-C5 antibody eculizumab and C5 deficiency on Escherichia coli (E. coli)-induced tissue factor function in plasma 
microparticles (TF-MP) and on coagulation (PTF1·2). Whole blood from healthy donors was preincubated with phosphate-buffered saline (PBS), 
eculizumab (Eculiz.) or control antibody (Ctrl.Ab.) prior to incubation with 1 × 107/ml E. coli (a,b). Whole blood from the C5-deficient individual 
was incubated with PBS, purified C5 or human serum albumin (HSA) prior to the incubation (c,d). E. coli-induced coagulation was measured by 
prothrombin fragment 1+2 (PTF1·2) in plasma using enzyme-linked immunosorbent assay (ELISA) (b,d), and expressed as a percentage of the 
positive control sample incubated with E. coli (set to 100%). TF-MP (a,c) are given in pg/ml. The results are expressed as means ± standard deviation 
(s.d.) for normal blood experiments (n = 6), and as means (line) and scatterplot of two experiments performed on two different days with C5-
deficient blood. *P < 0·05.
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presence of eculizumab in normal human blood did 
not affect platelet closure times or the coagulation kinetic 
readouts, implying that eculizumab does not interfere 
with normal hemostasis, and that C5 most probably 
does not play a role in hemostasis under physiological 
conditions. This is in agreement with the observation 
that C5-deficient individuals do not have a general 
bleeding tendency [18].
Keshari et al. recently observed that coagulation and 
hemostasis can be activated independently of significant 
complement activation, as infusion of FXa and phos-
phatidylcholine–phosphatidylserine in baboons did not 
activate complement [31]. Notably, in rodents and rab-
bits complement C6 and C7 deficiencies were accom-
panied by increased bleeding tendency or other 
coagulation disorders [13,14]. However, previous studies 
with human complement deficiencies, including C6 and 
C7, could not find such effects [15–17]. In the present 
study, the results from thromboelastometry, platelet 
function and coagulation tests imply that human C5 
deficiency neither causes hemostatic disorders nor patho-
logical coagulation kinetics.
The relatively high biological variation of PTF1·2 levels 
is due most probably to different levels of TF in high 
and low TF responders [32]. Eculizumab significantly 
reduced the E. coli-induced PTF1·2 when three, but not 
seven, groups were compared by one-way repeated-meas-
ures anova. This is due probably to weaker statistical 
power when many groups are compared. When E. coli 
with and without eclizumab were compared using a paired 
Student’s t-test, the effect on PTF1·2 was statistically sig-
nificant in all experiments. However, when the results 
after incubation with E. coli plus eculizumab were 
Table 1. Results from routine coagulation analysis of the C5D individ-
ual and healthy donors
Analyses
Results
Reference rangesHealthy donors C5Da
P-PT-INRb 1·0 ± 0·1 1·1 <1·2
P-APTTc (s) 34 ± 1·6 38 30–42
P-D-dimer (mg/l) n.d.d 0·3 <0·5
P-fibrinogen (g/l) n.d. 2·0 1·5-4·0
P-anti-thrombin (%) 102 ± 5·0 92 80–120
P-protein C (%) 99 ± 15 76 >70
P-protein S (%) 88 ± 12 97 >65
P-n-APCe-sensitivity 
ratio























Results from C5-deficient individual (n = 1) and healthy donors given 
in means ± standard deviation (s.d.) (n = 6). C5Da = complement com-
ponent 5-deficient individual; PT-INRb  =  prothrombin international 
normalized ratio; APTTc  =  activated partial thromboplastin time; 
n.d.d = not done; APCe = activated protein C; (GPL)f = immunoglobulin 
(Ig)G phospholipid units corresponding to 1 µg/ml of cardiolipin anti-
body; (MPL)g = IgM phospholipid units corresponding to 1 µg/ml of 
cardiolipin antibody; (SGU)h  =  standard IgG anti-beta-2-GPI unit; 
(SMU)i = standard IgM anti-beta-2-GPI unit.
Table 2. Thromboelastometry and platelet function analyses of blood 
from healthy donors and the C5D individual
Test Additions Healthy donors C5Da
CTb (s)c Undiluted 824 ± 159 968 ± 109
PBSd 1073 ± 143 1059 ± 370
Eculizumab 1059 ± 83 n.d.e
Control antibodyf 934 ± 94 n.d.
Alpha-angle (°)g Undiluted 47 ± 7·0 28 ± 1·0
PBS 41 ± 6·9 32 ± 8·5
Eculizumab 39 ± 4·6 n.d.
Control antibody 39 ± 5·2 n.d.
CFTh (s) Undiluted 259 ± 63 514 ± 22
PBS 333 ± 76 481 ± 187
Eculizumab 366 ± 72 n.d.
Control antibody 351 ± 61 n.d.
MCFi (smm)j Undiluted 48 ± 5·1 43 ± 2·3
PBS 46 ± 5·0 43 ± 1·5
Eculizumab 46 ± 3·7 n.d.
Control antibody 46 ± 4·3 n.d.
PFA200k (s) Undiluted 80 ± 21 106 ± 4·9
PBS 86 ± 24 121 ± 12
Eculizumab 94 ± 20 n.d.
Control antibody 103 ± 20 n.d.
Thromboelatometry was performed using non-activated thrombo-
elastometry (NATEM) reagents. Results are expressed as seconds, de-
grees or millimeter and are given as mean ± standard deviations (s.d.) 
for healthy donors (n = 6). Results for the C5D are from two analyses 
performed at two different days and are given as means ± s.d.
C5Da = complement component 5-deficient individual; CTb = clot-
ting time; (s)c =  second; PBSd; phosphate-buffered saline; n.d.e = not 
done; (°)g = degrees; CFTh = clot formation time; MCFi = maximum clot 
firmness; (mm)j  =  millimeter; PFA200k, Siemens Healthcare platelet 
function analyzer 200 closure time.
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compared with those of E. coli plus the control antibody, 
the results were significantly different in six of seven 
readouts. The significant inhibitory effect of eculizumab 
on the E. coli-induced coagulation in human whole blood 
indicated, however, an important role of C5 in bacteria-
induced coagulation. C5 blockade by eculizumab may 
reduce the complement-mediated lysis of live E. coli bac-
teria and reduce the free LPS level in plasma [33]. It 
was not possible to examine the effect of eculizumab on 
bacterial survival in this study, as we used heat-inactivated 
E. coli bacteria. Patients treated with eculizumab may 
possibly have a reduced risk of E. coli-induced coagula-
tion. As bacteria-induced thromboembolic events are 
significantly increased in PNH and catastrophic 
anti-phospholipid syndrome, two diseases indicative for 
eculizumab treatment, the putative protective effect of 
eculizumab on bacteria-induced thrombosis should be 
further examined [34].
This report indicates a significant role of C5 in the 
bacteria-induced TF up-regulation. We have previously 
reported that the E. coli-induced coagulation is predomi-
nantly TF-dependent [4]. In this study, we reveal that 
the E. coli-induced increase in TF mRNA levels in blood 
from healthy donors was virtually abolished by the addi-
tion of eculizumab, and was significantly enhanced in 
the C5D individual after reconstitution with purified C5. 
In reconstituted C5D blood, C5 reached a final concen-
tration of 50 mg/l, which is within the normal physiological 
range [35].
TF gene transcription can be induced rapidly by vari-
ous stimuli. In fact, Gregory et al. showed that monocyte 
TF mRNA expression is mainly regulated on the tran-
scriptional level, and that the TF mRNA half-life of 
approximately 1·5 h  is somewhat short [36]. In accord-
ance, monocytes were previously reported to have nearly 
undetectable amounts of TF stored in their cytoplasm in 
resting state [32]. Like N. meningitidis [5], E. coli induced 
TF surface expression on monocytes in a highly 
C5-dependent manner. We assumed that nearly all mono-
cyte TF surface expression originated from newly produced 
TF mRNA due to the significant role of C5 in the E. 
coli-induced TF mRNA up-regulation. However, the E. 
coli-induced monocyte TF surface expression was only 
partially blocked by C5 inhibition using eculizumab. Both 
Fig. 3. Correlations between coagulation activation measured as 
prothrombin fragment 1+2 (PTF1·2) in plasma and monocyte tissue 
factor (TF) surface expression (a) or tissue factor function in plasma 
microparticles (TF-MP) (b). The PTF1·2 level was analyzed by 
enzyme-linked immunosorbent assay (ELISA) and expressed in 
nmol/l. The TF surface expression on monocytes was analyzed by flow 
cytometry and expressed as median fluorescence intensity (MFI). The 
TF-MP levels were expressed in pg/ml. The Pearson’s correlation 
analyses were performed using GraphPad Prism. Results from separate 
experiments with each blood donor are included (n = 6).
Fig. 4. Effect of recombinant C5a on monocyte CD11b and tissue 
factor (TF) surface expression. Whole blood from healthy donors was 
incubated with phosphate-buffered saline (PBS) or increasing 
concentrations of purified human C5a for 10 min at 37°C (CD11b 
analysis) or 120 min (TF analysis) followed by flow cytometry. The 
results from separate experiments using blood from healthy blood 
donors (n = 4) are expressed as median fluorescence intensity 
(MFI) ± standard deviation (s.d.). The left y-axis indicates monocyte 
CD11b surface expression; samples added C5a (open circles) and 
samples added C5a and PMX53 (closed circle). The right y-axis 
indicates monocyte TF surface expression samples added C5a (open 
square) and samples added C5a and PMX53 (closed square).
A. Landsem et al.
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TF mRNA and monocyte surface TF were slightly increased 
in the absence of C5, indicating that other molecules and 
receptors are involved.
Egorina et al. previously showed that LPS is necessary 
to induce exocytosis of TF [32]. Also, there are several 
functional links between the LPS receptor CD14/TLR-4 
and CD11b or complement receptor CR3 (CD11b/CD18) 
[37]. We found that the TLR-4 inhibitor eritoran com-
pletely inhibited LPS-induced, but did not significantly 
reduce the E. coli-induced, TF surface expression. Together, 
these results indicate that E. coli-induced monocyte TF 
surface expression is C5 and TLR-4-dependent. E. coli 
bacteria also activates TLR-2 [38]. CD14 blockade has a 
broader effect on several TLRs than inhibition of TLR-4 
by eritoran as CD14 is a co-receptor of several TLRs, 
including TLR-2 and -4 [39]. This study indicates that 
combined inhibition of TLR-4 with eritoran and eculi-
zumab or combined inhibition of several TLRs by anti-
CD14 and eculizumab have similar effects on E. 
coli-induced TF, suggesting that TLR-4 is the main TLR 
involved.
In the present study, addition of human C5a alone to 
normal whole blood did not induce monocyte TF surface 
expression, despite its positive effect on CD11b. This is 
in contrast to a study by Janco et al., which showed that 
C5a induced procoagulant activity in isolated monocytes 
[40]. We have no explanation for this discrepancy, but a 
possible LPS contamination in the previously used C5a 
preparation should be considered. Importantly, in blood, 
C5a is immediately cleaved by carboxypeptidase N to 
Fig. 5. Effect of eculizumab, anti-CD14 or eritoran on Escherichia coli 
(E. coli)-induced monocyte tissue factor (TF) surface expression (a), 
tissue factor function in plasma microparticles (TF-MP) (b) and 
prothrombin fragment 1+2 (PTF1·2) levels in plasma (c). The blood 
samples from healthy donors were preincubated with eritoran, 
eculizumab (Eculiz.), anti-CD14 blocking monoclonal antibody 
(mAb) (aCD14), control antibody (Ctrl.Ab.) or a combination, as 
indicated, before they were either processed immediately (time zero 
samples) or incubated for 120 min at 37°C with phosphate-buffered 
saline (PBS) (control), 100 ng/ml ultrapure E. coli lipopolysaccharide 
(LPS) (closed circles) or 1 × 107/ml E. coli (open circles). Monocyte TF 
surface expression was measured using flow cytometry and given as 
median fluorescence intensity (MFI). TF-MP and PTF1·2 in plasma 
were analyzed using enzyme-linked immunosorbent assay (ELISA) 
and expressed as pg/ml and nmol/l, respectively. In the PTF1·2 
analysis, one data point of the control antibody data set was an outlier 
and replaced by the mean of this data set, both in the figure and the 
statistical analysis. All results are given as means ± standard deviation 
(s.d.) (n = 6). *P < 0·05.
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Fig. 6. Representative histograms from the flow cytometric analysis of the monocyte tissue factor (TF) surface expression in blood from one of six 
healthy blood donors. The median fluorescence (MFI) signal derived from the fluorescein isothiocyanate (FITC)-labeled anti-TF antibody is depicted 
at the x-axis and the monocyte count at the y-axis. The isotype control antibody data were nearly identical for all samples and not included in this 
illustration. (a) Whole blood was incubated for 120 min at 37°C with phosphate-buffered saline (PBS) (gray) or ultrapure E. coli lipopolysaccharide 
(LPS) (100 ng/ml) in the absence (yellow) or presence of eritoran (blue). (b) Whole blood was incubated for 120 min with PBS (gray) or E. coli 
(1 × 107/ml) in the absence (red) or presence of eritoran (purple) or a combination of eritoran and eculizumab (Eculiz.) (green).
(a)
(b)
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inactive C5a des-Arg [41] which, however, has some affin-
ity to C5aR and may induce CD11b up-regulation [42]. 
However, the selective C5aR1 antagonist PMX53 [43] 
ablated the C5a-induced CD11b expression on monocytes. 
This indicates that C5a-mediated induction of CD11b in 
human monocytes is wholly dependent upon C5aR1 sign-
aling, similar to that described for human neutrophils [44].
We have demonstrated earlier that E. coli-induced TF 
expression on plasma microparticles is partly C5-dependent 
[45], and have now verified this observation using 
C5-deficient blood reconstituted with C5. Importantly, TF 
negative microparticles may also induce coagulation 
through a procoagulant negatively charged surface and 
FXI [46]. In addition, LPS-induced shedding of TF posi-
tive plasma microparticles has been observed in high 
responders [32]. However, the high correlation between 
TF-MP and PTF1·2 levels found in our model suggests 
that TF positive plasma microparticles play a significant 
role in the coagulation activation and PTF1·2 formation. 
The E. coli-induced PTF1·2 was not significantly correlated 
with the TF surface expression on monocytes, due pos-
sibly to the limited number of blood donors. We dem-
onstrated that LPS induces TF-MP in a TLR-4-dependent 
manner in our model. E. coli-induced TF-MP levels, 
however, were significantly reduced only by the combined 
inhibition of CD14 or TLR-4 and C5, indicating a role 
for both TLR-4 and complement C5 for whole bacteria-
induced TF-MP. We have no explanation for the unex-
pected increase in the E. coli-induced TF-MP and PTF1·2 
levels by the control antibody. However, eculizumab did 
not have these effects, indicating that this is probably 
related to some unknown effects of the control antibody 
itself.
A limitation of this study is the inhibition of thrombin 
and the lack of endothelial cells as well as of blood flow 
in the whole blood model. This precludes us from study-
ing the effects of these factors in the experimental system. 
However, the contribution of TF from endothelial cells 
in sepsis is unclear, as a study on the endothelial TF-gene 
knock-out mice did not affect coagulation in an endotoxin 
model [47]. The TF-positive microparticles seem to be 
an important contributor to TF’s effect in sepsis [48]. 
Nevertheless, so far the current whole blood model is 
the best available model to study the role of complement 
ex vivo in interaction with other biological systems. Another 
limitation is that only one C5D individual was included 
in our study, as this deficiency is extremely rare. It is 
therefore possible that our observations from this C5D 
individual do not reflect the theoretical entirety of C5D 
individuals in general.
Taken together, this study revealed that C5 plays a criti-
cal role together with TLR-4 in E. coli-induced coagulation 
without affecting physiological hemostasis. Consequently, 
C5-deficient and patients treated with eculizumab may 
have a reduced risk of E. coli-induced coagulation.
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